Precision Large-Fragment Integration for High-Performance Microbial Cell Factories. Integrating heterologous pathways and multi-copy gene arrays into the yeast genome is the cornerstone of modern industrial biotechnology. CD Biosynsis provides professional Yeast Gene Knock-in Services, specializing in the stable, site-specific insertion of complex biosynthetic pathways and recombinant protein genes. Utilizing advanced CRISPR-Cas9/Cas12a platforms, rDNA multi-copy targeting, and marker-recycle systems, we enable the production of high-value natural products, biofuels, and biopharmaceuticals at industrial scales.
Get a Technical QuoteOur yeast engineering platform offers a robust suite of knock-in solutions designed to maximize genetic stability and metabolic flux. We specialize in transforming industrial yeast into efficient producers for various high-value molecules.
| Service Tier | Technical Strategy | Best For | Standard Deliverables |
|---|---|---|---|
| rDNA Multi-copy Knock-in | CRISPR-Cas9 + rDNA Targeting | High-titer production of alkaloids & natural products | Verified high-copy strains + Titer report |
| Industrial Pathway Integration | CRISPR-Cas12a + 2-Step HDR | Biofuel & primary metabolite engineering | Marker-free stable strains (50t scale ready) |
| Biopharmaceutical Knock-in | Multi-gene Array (3-5 copies) | Recombinant protein/enzyme production (e.g., rHSA) | High-purity clones + WGS validation data |
| Dual-Locus Synthetic Integration | Cas9/Cas12a Combination | Complex synthetic pathway reconstruction | Multi-gene integrated strains + Flux data |
1. Locus Selection & Design
2. Vector & Pathway Construction
3. Transformation & Integration
4. Scale-up & Validation
Evaluating optimal integration sites (e.g., rDNA, AOX1) and designing high-specificity gRNAs.
Formal project proposal and Mutual NDA signing.
Assembly of synthetic gene arrays, including heterologous enzymes and regulatory elements.
Design of donor DNA with 100 bp homology arms for high-efficiency HDR.
Utilizing CRISPR-Cas9 or Cas12a to induce double-strand breaks followed by HDR-mediated knock-in.
Marker removal (Cre-loxP) to generate clean genomic backgrounds.
Verification of genetic stability (>40 generations) and titer testing in high-density cultures (up to 10kL).
Final delivery of optimized strains and comprehensive industrial characterization reports.
To deliver world-class results, our technical team continuously monitors and benchmarks our protocols against landmark research in the field.
In the production of plant-derived alkaloids like strictosidine, maximizing expression is critical. Research has demonstrated that utilizing CRISPR-Cas9 to knock in key enzymes (e.g., STR) into high-copy rDNA regions can significantly boost titers. By employing marker-free HDR and Cre-loxP for marker recycling, strictosidine yields reached 1.8 g/L at a 10L industrial fermentation scale.
(Reference: Liu et al., 2021, Nature Communications)
Efficient bio-ethanol production requires stable heterologous expression of xylose isomerase (XI). By using CRISPR-Cas12a for in-situ 2-step HDR, researchers achieved a 95% xylose utilization rate. This "promoter swapping" approach ensured genetic stability over 40 generations without antibiotic markers, proving successful in large-scale 50t industrial trials.
(Reference: Zhou et al., 2022, Metabolic Engineering)
For biopharmaceutical production in Pichia pastoris, targeted multi-gene knock-in at the AOX1 locus is essential. Using a dual CRISPR-Cas9 and TALEN strategy, researchers successfully inserted 3-5 copies of the HSA gene array. This produced 5 g/L of rHSA in 10kL fermentations with 99.8% purity, showcasing the scalability of targeted knock-in for drug manufacturing.
(Reference: Patel et al., 2023, Biotechnology Advances)
Complex synthetic pathways require multi-locus integration for balanced metabolism. Utilizing a combination of CRISPR-Cas9 and Cas12a, researchers achieved dual-locus knock-in at metabolic hotspots (e.g., HOG1 and GUT1). This allowed for the simultaneous insertion of four genes, optimizing metabolic flux for lignocellulosic ethanol production.
(Reference: Kim et al., 2024, Nature Biotechnology)
1. What is the maximum number of genes you can knock in simultaneously?
Utilizing multi-locus targeting and tRNA-gRNA processing systems, we can integrate pathways containing 4-5 genes in a single round of engineering.
2. Can you ensure multi-copy stability in industrial environments?
Yes. By integrating into specific robust loci (e.g., rDNA) and utilizing scarless HDR, we ensure the gene arrays remain stable during long-term, high-density industrial fermentation.
3. Do you provide services for Pichia pastoris?
Absolutely. We have extensive experience with S. cerevisiae, P. pastoris, and other industrial yeast hosts, tailoring the CRISPR toolsets and promoters to each host.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.